NCT02076646 2022-04-14
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Philogen S.p.A.
Phase 1/2 Unknown
Clinical Trials
6 trialsNCT00070343 2014-01-06
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
National Cancer Institute (NCI)
Phase NA Unknown
NCT00991250 2010-02-05
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
SentoClone AB
Phase 2 Unknown
NCT00779714 2008-10-24
ChemoSensMM
University of Wuerzburg
Phase 3 Unknown
NCT00226473 2006-06-21
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
Dermatologic Cooperative Oncology Group
Phase 4 Unknown
NCT00006200 2005-06-24
Thalidomide and Dacarbazine for Metastatic Melanoma
National Center for Research Resources (NCRR)
Phase 2 Unknown